These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 8420183

  • 1. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls.
    Cordes M, Hierholzer J, Schelosky L, Poewe W, Cordes I, Horowski R, Eichstaedt H, Schmidt D, Felix R.
    Adv Neurol; 1993; 60():525-8. PubMed ID: 8420183
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W, Grundmann M, Huber G.
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL.
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [Abstract] [Full Text] [Related]

  • 10. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G, Chierichetti F, Rossato A, Cagnin A, Fabbri M, Dam M, Ferlin G, Battistin L.
    J Neural Transm Suppl; 1995 Jan; 45():113-22. PubMed ID: 8748616
    [Abstract] [Full Text] [Related]

  • 11. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J, Cordes M, Schelosky L, Barzen G, Poewe W, Henkes H, Keske U, Horowski R, Felix R.
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [Abstract] [Full Text] [Related]

  • 12. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123.
    Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P.
    Arch Neurol; 1993 May; 50(5):509-12. PubMed ID: 8489408
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.
    Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG.
    J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.